Coverage for weight loss is a different story: only 13 states cover obesity-indicated GLP-1s as of January 2026, and that number has been shrinking as states face budget pressure
Recognizing this brain-obesity link is critical for protecting your long-term cognitive health, and the good news isyour brain can heal
RAA: rapid-acting insulin analogue
A study in the New England Journal of Medicine highlighted that participants using a GLP-1 experienced weight loss that included both fat and lean mass
3.3.2 Safety Outcome We examined the incidence of several safety outcomes, including total adverse events, serious adverse events, adverse events leading to discontinuation, urinary tract infection, deaths, hypoglycaemia, diarrhoea, nausea, injection-site-related events, volume-related events, pancreatic events, acute renal disorders, genital infection, adjudicated cardiovascular events, upper respiratory tract infection, headache, vomiting and ketosis
While the outcomes of such early test trials are not binding on other claims, they are often critical to help the parties gauge how juries are likely to respond to certain evidence and testimony that will be repeated throughout the litigation, potentially facilitating Ozempic settlement negotiations that would avoid the need for each individual case to be set for trial in the future